Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.22 million shs	N/A
BPMC Blueprint Medicines	$129.30 0.0%	$117.02	$73.04 ▼ $129.49	$8.35B	0.89	1.39 million shs	3.57 million shs
EVTCY Evotec	$4.07 -2.4%	$4.13	$14.22 ▼ $26.57	$1.34B	0.98	2,407 shs	29,351 shs
FGEN FibroGen	$7.15 -2.7%	$6.97	$4.50 ▼ $38.25	$28.90M	0.74	76,133 shs	59,782 shs
HCM HUTCHMED	$16.04 +0.4%	$14.92	$11.51 ▼ $21.50	$2.80B	0.52	94,291 shs	28,642 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+2.72%	-60.35%
BPMC Blueprint Medicines	0.00%	+0.80%	+0.85%	+59.95%	+11.51%
EVTCY Evotec	-2.40%	-3.10%	-4.68%	+27.99%	-20.51%
FGEN FibroGen	0.00%	+25.66%	-7.29%	+3.17%	-68.34%
HCM HUTCHMED	0.00%	+0.92%	-9.48%	+16.91%	-3.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	2.9411 of 5 stars	3.1	0.0	0.0	4.7	0.6	2.5	1.3
BPMC Blueprint Medicines	1.2222 of 5 stars	2.1	2.0	0.0	0.0	2.9	0.8	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	4.7276 of 5 stars	3.3	4.0	0.0	4.7	3.8	3.3	0.6
HCM HUTCHMED	1.6191 of 5 stars	2.0	3.0	0.0	0.0	2.5	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.81% Downside
EVTCY Evotec	0.00	N/A	N/A	N/A
FGEN FibroGen	2.50	Moderate Buy	$250.00	3,396.50% Upside
HCM HUTCHMED	2.00	Hold	$19.00	18.45% Upside

Current Analyst Ratings Breakdown

Latest BPMC, EVTCY, FGEN, ALLK, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
BPMC Blueprint Medicines	$508.82M	16.41	N/A	N/A	$4.70 per share	27.51
EVTCY Evotec	$572.16M	2.35	$0.04 per share	105.53	$2.52 per share	1.62
FGEN FibroGen	$29.62M	0.98	N/A	N/A	($50.89) per share	-0.14
HCM HUTCHMED	$630.20M	4.44	$0.29 per share	55.84	$4.43 per share	3.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	198.92	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	9.93	∞	N/A	20.85%	16.02%	7.81%	N/A
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.99	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)

Latest BPMC, EVTCY, FGEN, ALLK, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/6/2025	Q2 2025	ALLK Allakos	-$0.24	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
BPMC Blueprint Medicines	1.01	2.80	2.75
EVTCY Evotec	0.53	2.57	2.50
FGEN FibroGen	N/A	2.02	1.98
HCM HUTCHMED	0.08	2.83	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
BPMC Blueprint Medicines	N/A
EVTCY Evotec	N/A
FGEN FibroGen	72.71%
HCM HUTCHMED	8.82%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
BPMC Blueprint Medicines	4.21%
EVTCY Evotec	N/A
FGEN FibroGen	3.07%
HCM HUTCHMED	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable

BPMC, EVTCY, FGEN, ALLK, and HCM Headlines

Recent News About These Companies

HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume - What's Next?

July 9, 2025 | marketbeat.com

HUTCHMED to Announce 2025 Half-Year Financial Results

July 3, 2025 | globenewswire.com

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

June 30, 2025 | globenewswire.com

HUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" Rating

June 27, 2025 | marketbeat.com

HUTCHMED (China) Limited (HCM.L) - Yahoo Finance

June 26, 2025 | nz.finance.yahoo.com

HUTCHMED (China) Limited (HCM) - Yahoo Finance

June 26, 2025 | au.finance.yahoo.com

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - Nasdaq

June 25, 2025 | nasdaq.com

How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%

June 23, 2025 | zacks.com

Paycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'

June 22, 2025 | seekingalpha.com

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?

June 17, 2025 | marketbeat.com

HUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street Zen

June 14, 2025 | marketbeat.com

Hutchmed introduces new share options and LTIP awards

June 11, 2025 | uk.investing.com

HUTCHMED Grants Share Options and LTIP Awards to Boost Talent Retention

June 10, 2025 | tipranks.com

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

June 5, 2025 | zacks.com

China accepts NDA for sintilimab and fruquintinib combo in kidney cancer

June 4, 2025 | msn.com

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

June 4, 2025 | prnewswire.com

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

June 4, 2025 | globenewswire.com

HUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer Treatment

June 1, 2025 | tipranks.com

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

June 1, 2025 | globenewswire.com

HUTCHMED to Present Promising Oncology Data at 2025 ASCO Meeting

May 22, 2025 | tipranks.com

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMC, EVTCY, FGEN, ALLK, and HCM Company Descriptions

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)

As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Blueprint Medicines NASDAQ:BPMC

$129.30 -0.03 (-0.02%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$129.30 0.00 (0.00%)

As of 07/11/2025 05:23 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Evotec OTCMKTS:EVTCY

$4.07 -0.10 (-2.40%)

As of 07/11/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

FibroGen NASDAQ:FGEN

$7.15 -0.20 (-2.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.30 +0.15 (+2.10%)

As of 07/11/2025 07:00 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

HUTCHMED NASDAQ:HCM

$16.04 +0.07 (+0.44%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$16.05 +0.01 (+0.06%)

As of 07/11/2025 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time